ZANOVELLO, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.027
AS - Asia 7.615
EU - Europa 3.582
AF - Africa 1.316
SA - Sud America 1.293
OC - Oceania 117
Continente sconosciuto - Info sul continente non disponibili 51
Totale 30.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.353
SG - Singapore 2.280
CN - Cina 1.576
VN - Vietnam 1.028
HK - Hong Kong 808
BR - Brasile 784
IT - Italia 490
DE - Germania 425
FI - Finlandia 395
FR - Francia 290
IN - India 229
SE - Svezia 217
UA - Ucraina 192
GB - Regno Unito 180
BD - Bangladesh 159
RU - Federazione Russa 150
PL - Polonia 147
IQ - Iraq 117
AR - Argentina 104
KR - Corea 99
JP - Giappone 95
NL - Olanda 94
TR - Turchia 94
CA - Canada 92
PH - Filippine 85
ZA - Sudafrica 80
SA - Arabia Saudita 73
PK - Pakistan 66
CI - Costa d'Avorio 65
CO - Colombia 61
AT - Austria 59
EC - Ecuador 59
IE - Irlanda 59
UZ - Uzbekistan 59
ID - Indonesia 57
TN - Tunisia 53
ES - Italia 52
VE - Venezuela 51
KH - Cambogia 50
CH - Svizzera 48
CL - Cile 47
AO - Angola 46
MX - Messico 46
MA - Marocco 45
AZ - Azerbaigian 44
JO - Giordania 44
AE - Emirati Arabi Uniti 43
AL - Albania 43
CR - Costa Rica 42
HU - Ungheria 42
NP - Nepal 42
BE - Belgio 41
ET - Etiopia 41
HN - Honduras 41
PE - Perù 41
MY - Malesia 40
PY - Paraguay 40
RS - Serbia 40
SI - Slovenia 39
KG - Kirghizistan 38
RE - Reunion 38
RO - Romania 38
UY - Uruguay 38
EE - Estonia 37
GT - Guatemala 37
KE - Kenya 37
BO - Bolivia 36
GR - Grecia 36
IR - Iran 36
LY - Libia 36
TH - Thailandia 36
DO - Repubblica Dominicana 35
DZ - Algeria 35
EG - Egitto 35
GE - Georgia 35
JM - Giamaica 35
YT - Mayotte 35
MD - Moldavia 34
ME - Montenegro 34
ZM - Zambia 34
BJ - Benin 33
BY - Bielorussia 33
DK - Danimarca 33
IL - Israele 33
MU - Mauritius 33
BB - Barbados 32
BG - Bulgaria 32
CW - ???statistics.table.value.countryCode.CW??? 32
UG - Uganda 32
GH - Ghana 31
LA - Repubblica Popolare Democratica del Laos 31
LU - Lussemburgo 31
RW - Ruanda 31
TW - Taiwan 31
BW - Botswana 30
BZ - Belize 30
GN - Guinea 30
HR - Croazia 30
PA - Panama 30
PT - Portogallo 30
Totale 28.565
Salva come PNG Salva come JPEG
Città #
Ashburn 1.804
Fairfield 1.642
Woodbridge 1.404
Singapore 1.375
San Jose 1.183
Houston 1.115
Chandler 1.009
Ann Arbor 983
Hong Kong 729
Jacksonville 642
Seattle 594
Wilmington 587
Cambridge 569
Beijing 324
Ho Chi Minh City 286
Princeton 276
Boardman 246
San Diego 224
Hanoi 223
Helsinki 220
Los Angeles 206
Santa Clara 188
Padova 165
Lauterbourg 138
Nanjing 118
Des Moines 112
New York 97
Council Bluffs 90
Bytom 89
Dong Ket 81
Roxbury 78
Medford 76
Guangzhou 71
Da Nang 64
Munich 64
São Paulo 64
Abidjan 62
Hefei 61
Seoul 51
Tokyo 51
Chicago 49
Baghdad 47
Phnom Penh 47
Tashkent 47
Orem 46
Dublin 44
Amman 43
London 43
Dallas 41
Hebei 41
Baku 39
Buffalo 39
Johannesburg 39
Milan 39
Luanda 37
Nanchang 37
Frankfurt am Main 36
Haiphong 36
Vienna 36
Jeddah 34
Montevideo 34
Addis Ababa 33
Bishkek 32
Kampala 32
Lusaka 32
Montreal 32
Nairobi 32
San José 32
Shanghai 32
Atlanta 31
Shenyang 31
Accra 30
Amsterdam 30
Brooklyn 30
Conakry 30
Cotonou 30
Tbilisi 30
Bridgetown 29
Kigali 29
Tianjin 29
Nuremberg 28
Kingston 27
Lima 27
Nouakchott 27
Panama City 27
Podgorica 27
Warsaw 27
Dakar 26
Norwalk 26
Ouagadougou 26
Tallinn 26
Vientiane 26
Andorra la Vella 25
Belo Horizonte 25
Denver 25
Dushanbe 25
Kingstown 25
Willemstad 25
Belgrade 24
Changsha 24
Totale 19.319
Salva come PNG Salva come JPEG
Nome #
A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer 387
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. 385
A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors 370
A circulating miRNA assay as a first-line test for prostate cancer screening 359
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells 356
WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia 356
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells 317
Cellular pharmacology of PNU-159682, a liver microsomal metabolite of methoxymorpholinyl doxorubicin (Nemorubicin; MMDX) 310
Reverse immunoediting: When immunity is edited by antigen 303
Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes 299
Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer 297
Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells 294
MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis 292
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. 292
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. 290
Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells 288
Circulating miRNA-375 as a potential novel biomarker for active Kaposi’s sarcoma in AIDS Patients 279
Reconstruction of gene regulatory modules from RNA silencing of IFN-α modulators: Experimental set-up and inference method 275
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma 268
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate 263
MODULATION OF MICRORNA EXPRESSION IN HUMAN T CELL DEVELOPMENT: TARGETING OF NOTCH3 BY MIR-150 263
A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer 256
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer 253
Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1 252
Dissecting the molecular regulatory networks in human myeloid-derived suppressor cells 251
Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination 247
A paclitaxel-hyaluronan bioconjugate exerts a high in vivo therapeutic activity against ovarian cancer 245
Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization 244
Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies 242
miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia 242
Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression 236
Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia 234
Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy 233
Study of Some Early Immunological Parameters In Aging Humans 231
Role of microRNAs in HTLV-1 infection and transformation 228
Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area 227
Chemotactic Cues for NOTCH1-Dependent Leukemia 226
Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow 223
Cancer rejection by the immune system: forcing the check-points of tumor immune escape. 221
A gene expression signature associated with survival in metastatic melanoma 220
Myeloid-derived suppressor cell role in tumor-related inflammation 216
Common cancer biomarkers 212
An integrative framework identifies alternative splicing events in colorectal cancer development. 211
DNA immunization in mice against virus-induced tumor antigens. 211
Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis 207
CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. 207
Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy 206
Immunotherapy for EBV-associated malignancies 204
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST) 204
Human miRNome profiling in colorectal cancer and liver metastasis development 203
Responsiveness to hedgehog pathway inhibitors in t-cell acute lymphoblastic leukemia cells is highly dependent on 5′ amp-activated kinase inactivation 201
Melanoma-restricted genes 199
Role of arginine metabolism in immunity and immunopathology. 198
ADOPTIVE TRANSFER OF LYMPHOKINE-ACTIVATED KILLER-CELLS LOADED WITH 4'-DEOXY-4'-IODODOXORUBICIN - THERAPEUTIC EFFECT IN MICE BEARING LUNG METASTASES 195
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells 194
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer 194
Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors 194
Characterization of Clinical and Molecular Features Related to the Downregulated Expression of μ-Protocadherin in Colorectal Cancer. 193
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination 192
ANTITUMOR EFFICACY OF LYMPHOKINE-ACTIVATED KILLER-CELLS LOADED WITH RICIN AGAINST EXPERIMENTALLY INDUCED LUNG METASTASES 191
Natural history of M-MSV tumors in mice carrying endogenized Moloney leukemia virus. 191
Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. 191
Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. 189
Lack of T-cell mediated cytotoxicity in M-MSV system depending on H-2 haplotypes. 187
L-arginine metabolism in myeloid cells controls T-lymphocyte functions 187
Calcium and Inositolphosphates In the Activation of T-cell-mediated Cytotoxicity 187
IL4R alpha(+) Myeloid-Derived Suppressor Cell Expansion in Cancer Patients 186
DNA-based vaccination against tumors expressing the P1A antigen 186
Regulation of immune responses by L- arginine metabolism 185
Tolerance to viral antigens in Mov-13 mice carrying endogenized Moloney-murine leukemia virus. 184
CTL Analysis for Tumor Vaccines. 184
MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas 184
Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases 183
Derangement of immune responses by myeloid suppressor cells 182
Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity 182
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells 181
Tumor-induced immune dysfunctions caused by myeloid suppressor cells 179
Functional avidity-driven activation-induced cell death shapes CTL immunodominance. 179
Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. 178
GM-CSF and IL-6 induce tolerogenic myeloid-derived suppressor cells through C/EBP beta and allow long term islet allograft survival 178
Impact of gamma-chain cytokines on EBV-specific T cell cultures 176
Lack of M-MuSV tumour regression associated with T lymphocyte tolerance. 176
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results 174
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150 172
Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. 172
Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma 171
INHIBITION OF PROTEIN-TYROSINE PHOSPHORYLATION PREVENTS T-CELL-MEDIATED CYTOTOXICITY 171
CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes 171
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice 171
Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel 169
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPbeta Transcription Factor. 169
Myeloid-derived suppressor cell heterogeneity and subset definition 169
Extracellular ATP as a possible mediator of cell-mediated cytotoxicity 166
Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: A novel target for therapeutic intervention 165
Role of infectious virus expression and immune response in retrovirus-induced oncogenesis. 165
Functional activityin vivo of effector T cell populations III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone 165
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer 162
The microRNA regulatory network in normal- and HTLV-1-transformed T cells. 161
Loss of zfp36 expression in colorectal cancer correlates to wnt/ ß-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of zeb1, sox9 and macc1 161
Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8(+) T cell parameters 160
Totale 22.135
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.504
article - articoli 83.040
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 917
Totale 169.461
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021177 0 0 0 0 0 0 0 0 0 0 0 177
2021/20222.385 68 302 350 146 80 164 201 214 87 47 290 436
2022/20231.901 403 234 56 232 290 259 10 116 187 15 68 31
2023/2024855 48 107 91 55 84 100 73 62 31 27 80 97
2024/20253.163 24 166 140 119 463 143 124 294 298 132 498 762
2025/202613.544 461 1.184 1.815 2.202 1.142 690 1.859 1.269 1.512 814 565 31
Totale 30.073